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Edited by Beat ImhofAbstract We have investigated immunoproteasomes in human
ﬁbroblasts during replicative senescence. Unlike levels of consti-
tutive proteasome catalytic subunits and 26S proteasome regula-
tory subunits, levels of immunosubunits did not decrease
dramatically in senescent cells. However, the induction of imm-
unosubunits by interferon-c (IFN-c) was lost in senescent cells.
In contrast, levels of the 11S proteasome regulator, PA28, were
increased by IFN-c even in senescent cells, and both immunosu-
bunits and PA28 increased with the reversible growth arrest in
conﬂuent cell cultures. The results highlight diﬀerences in the
mechanisms of regulation of immunoproteasomes compared to
constitutive proteasomes and in the irreversible growth arrest
of senescent cells compared to reversible contact-induced growth
arrest.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Proteasomes play a major role in intracellular protein turn-
over both in the ubiquitin-proteasome pathway [1] and in
ubiquitin-independent pathways [2]. In animal cells protea-
somes can exist in a number of diﬀerent forms. The core pro-
teolytic 20S proteasome contains four rings of seven subunits
in a a7b7b7a7 arrangement. This can associate with two 19S
regulatory complexes to form the 26S proteasome that is re-
quired in the ubiquitin-proteasome pathway or with other reg-
ulators such as 11S (PA28) regulatory complexes. The catalytic
beta subunits (b1, b2, b5) of constitutive proteasomes have
close homologues that are inducible by interferon-c (IFN-c).
These proteasome immunosubunits, b1i, b2i, and b5i, are incor-
porated into immunoproteasomes that have altered cleavage
speciﬁcities [3,4] and subcellular distribution [5]. They have
important functions in MHC class I immune responses to viral
infection and tumour cells but their precise role is not yet clearAbbreviations: AMC, 7-amido-4-methylcoumarin; CT-L, chymotryp-
sin-like; CPD, cumulative population doublings; IFN-c, interferon-c;
PGPH, peptidyl-glutamyl peptide hydrolase; T-L, trypsin-like
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doi:10.1016/j.febslet.2006.06.029[6,7]. Two types of PA28 subunits, a and b, that are induced by
IFN-c, form a hetero-heptameric complex that also plays a
role in MHC class I restricted antigen presentation [8].
IFN-c is a cytokine that is released in the early stages of
viral infection. Interferons inhibit cell growth and exhibit
anti-tumour activity through the induction of proteins such
as p53 and p21 [9–12]. Defects in IFN-induced signalling
and expression can be associated with cell immortalization
[10]. IFN-c inducible proteins including p21 and IFI 16, are
known to play a part in cellular senescence [11,12], while
the senescence associated Tid1 protein is known to modulate
IFN-c and NFjB signalling [13]. Normal human ﬁbroblasts
exhibit limited growth potential and after a limited number
of cumulative population doublings (CPD) they remain via-
ble but undergo an irreversible growth arrest known as repli-
cative senescence [12]. Proteasome properties have been
found to change both during ageing and during replicative
senescence (reviewed in [14]). A decrease in proteasome activ-
ity with increasing age probably accounts for the observed
age-related increases in oxidized and other modiﬁed forms
of proteins and contributes to the decreased degradation of
damaged proteins that are associated with age-related dis-
eases [15,16].
In this study, we have investigated the eﬀects of IFN-c on
immunoproteasome complexes in senescent cells in order to
gain a better understanding of the regulation of immunopro-
teasomes in relation to cell proliferation and senescence. The
results show marked diﬀerences in mechanisms of regulation
of constitutive proteasome levels, of immunoproteasome sub-
units and of IFN-c inducible PA28. They also highlight the dif-
ferences in replicative senescence compared to contact-induced
reversible growth arrest, and demonstrate the importance of
immunoproteasomes in healthy ageing.2. Materials and methods
2.1. Cell culture
Human embryonic ﬁbroblasts WI38 were obtained from the Euro-
pean Collection of Cell Cultures and were maintained in Dulbecco’s
modiﬁed Eagle’s medium (Sigma) supplemented with 10% (v/v) foetal
bovine serum, penicillin/streptomycin (50 U/ml/50 lg/ml), 2 mM gluta-
mine, and 1% non-essential amino acids (complete medium). WI38
ﬁbroblasts were sub-cultured at a split ratio 1:2 when cells reached con-
ﬂuence, until they entered senescence. In the experimental procedures
described below early passage (young; CPD < 25) and late passage
(senescent) WI38 cells were used. In the case of the experiments shown
in Fig. 1, cells reached senescence at 36–37 CPD, whereas for otherblished by Elsevier B.V. All rights reserved.
Fig. 1. Proteasome peptidase activities in extracts from early passage/
young and late passage/senescent WI38 ﬁbroblasts. Proteasome
activities were measured in cell extracts as described in Section 2 by
subtracting activities obtained in the presence of proteasome inhibitor
to give proteasome CT-L, PGPH/caspase-like, and T-L activity in
early and late passage cells that were cultured in the presence or in the
absence of IFN-c. Activities (mean relative ﬂuorescence units per mg
protein ± S.E.M.) are the average from three independent experiments.
Statistical analysis has shown that there is a signiﬁcant diﬀerence
between early untreated and c-IFN treated cells (P < 0.05). Diﬀerences
in activity in late passage cells are not statistically signiﬁcant.
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44–48 CPD. For IFN-c experiments, cells were grown in the absence
and presence of 250 U/ml human IFN-c for 24 h.
2.2. Proteasome activity assays
Cells were lysed in 20 mM Tris/HCl buﬀer, pH 7.5, containing 5 mM
ATP, 10% glycerol and 0.2% NP-40. Chymotrypsin-like (CT-L), tryp-
sin-like (T-L), and peptidyl-glutamyl peptide hydrolase (PGPH)/cas-
pase-like activities of the proteasome in crude extracts were assayed
with Suc-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (AMC), N-t-
Boc-Leu-Ser-Thr-Arg-AMC, and N-Cbz-Leu-Leu-Glu-AMC, respec-
tively, for 30 min at 37 C, as described previously [15]. Proteasome
activity was determined as the diﬀerence between the total activity of
crude extracts with each substrate and the remaining activity in the
presence of 20 lMMG132 in 25 mM Tris/HCl buﬀer, pH 7.5, contain-
ing 5 mM ATP. Assays were standardized between cell extracts by
using equal amounts of cellular protein as determined by the Bradford
method.
CT-L activity of 26S proteasomes was also assayed in fractions from
the gel ﬁltration column and subsequently in crude cell extracts with-
out subtracting values from inhibited samples. In these experiments,
extracts were prepared in 20 mM Tris/HCl buﬀer, pH 7.5, containing10% glycerol and 0.2% NP-40 (no ATP) and assays were carried out
in 25 mM Tris/HCl buﬀer, pH 7.5, containing 5 mM ATP for 20 min
at 37 C. 20S proteasome activity in fractions from the gel ﬁltration
column was assayed in 50 mM HEPES/KOH buﬀer, pH 7.5, contain-
ing 0.02% SDS. Gel ﬁltration experiments were carried out using a
Superose 6 column equilibrated in buﬀer containing 100 mM KCl ex-
cept where stated in experiments designed to maintain intact PA28-20S
proteasome complexes, in which case a low salt buﬀer was required
[17].
2.3. Antibodies and immunoblotting
Cell lysates were separated by SDS–PAGE and transferred to nitro-
cellulose membranes. Immunoblotting was performed using antibodies
that were either kindly provided by Dr. K. Hendil (University of
Copenhagen, Denmark) or purchased from Aﬃniti Research Products
Ltd. Antibodies used were speciﬁc for proteasome subunits: a7 and/or
a6 for total 20S proteasome core, b5i, b2i, b1i for level of immunopro-
teasomes, b1 for constitutive catalytic subunits, S4 or S5a for level of
19S regulatory complexes and thus of 26S proteasomes, and 11S regu-
lator PA28a for the level of PA28/PA28-20S proteasome complexes.
Detection was by secondary antibodies conjugated with horseradish
peroxidase and enhanced chemiluminescence. Equal protein loading
was veriﬁed by stripping the membranes and reprobing them with
b-actin antibody (Santa Cruz Biotechnology Inc.).
2.4. Immunoﬂuorescence microscopy
For investigation of the localization of immunoproteasome sub-
units, cells were grown on coverslips, ﬁxed with 4% freshly prepared
paraformaldehyde in PBS and permeabilized with 0.2% Triton X-100
in PBS. Alternative ﬁxing with methanol gave similar results. Immu-
nolabelling of proteasomes was carried out using antibodies against
b1i, b2i and b5i immunosubunits. The antibodies were diluted in PBS
containing 0.1% Tween-20 and 3% BSA (blocking buﬀer); the second-
ary anti-mouse IgG/FITC-conjugated antibody was diluted 1:300 in
blocking buﬀer. Images were taken using a Leica TCS SP-1 confocal
laser scanning microscope. Controls to demonstrate the speciﬁcity of
the antibody used were: (a) the use of normal serum instead of the
reactive antibody and (b) omission of primary antibody. All controls
appeared free of any immunoﬂuorescence background.3. Results
3.1. Proteasome activity changes in response to IFN-c
Eﬀects of IFN-c treatment on proteasome activity were mea-
sured in early and late passage cells. All three peptidase activi-
ties (CT-L, T-L and PGPH/caspase-like) were substantially
decreased in senescent cells (Fig. 1) consistent with previous
ﬁndings [15]. However, IFN-c had very diﬀerent eﬀects in young
and senescent cells. In the young cells proteasome CT-L and
PGPH activities were increased by IFN-c, whereas in senescent
cells no signiﬁcant change in these activities was observed.
In order to evaluate the possible contribution of other pro-
teases to the hydrolysis of proteasome substrates and the need
for assays carried out both with and without proteasome
inhibitor, WI38 cell extracts were fractionated by gel ﬁltration
[17,18]. The results of the analysis showed that although the
majority of the CT-L activity could be accounted for by pro-
teasomes, there was a small contribution (10–30%) from other
lower molecular weight protease activity. Immunoblot analysis
showed that there was very little, if any, free 19S complex in
these cells. Assays in the presence of SDS showed some 20S
proteasome activity, presumably derived from PA28-20S pro-
teasome complexes that would dissociate under the conditions
used in these experiments. When columns were run under con-
ditions to preserve PA28-20S complexes [17], gel ﬁltration and
immunoblot analysis of fractions from early passage cells be-
fore and after IFN-c treatment showed that the majority of
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accounted for by PA28-20S or hybrid complexes, as observed
in other cell types and documented previously [17,18]. Thus in-
creases in proteasome peptidase activities measured in cell ex-
tracts from cells treated with IFN-c (Fig. 1) can be accounted
for in part by the increase in the PA28 activator and in part by
changes in the relative levels of immunoproteasomes compared
to constitutive proteasomes (see below).
We determined whether the loss of IFN-c eﬀect on protea-
some activity during replicative senescence was gradual or
not by measuring proteasome CT-L activity in cell lysates from
WI38 cells at increasing cell population doublings. As shown
in Fig. 2, activity increased following IFN-c treatment in early
passage cells. Any diﬀerences in the precise fold stimulation of
activity from that in Fig. 1 can be explained by diﬀerences in
extraction buﬀer and assay conditions between the two sets
of experiments that are detailed in Section 2 and ﬁgure legends.
As cells approached replicative senescence (at CPD 43) the in-
crease in proteasome activity in response to IFN-c was re-
duced, and when cells became irreversibly growth arrested
(at CPD46 in these experiments), IFN-c treatment failed to
stimulate proteasome CT-L activity. Although the batches of
cells in these experiments (Fig. 2) underwent more population
doublings before becoming senescent than cells used for Fig. 1
(36–37 CPD, kept in culture for 1 month), the eﬀects observed
were exactly the same.
3.2. IFN-c treatment increases levels of inducible
immunoproteasome subunits in early passage WI38
ﬁbroblasts but not in senescent cells
From the assays of proteasome peptidase activities in crude
extracts it is not possible to determine the relative contribution
of the diﬀerent catalytic complexes [18]. We therefore investi-
gated whether the loss of upregulated proteasome activities fol-
lowing IFN-c treatment in senescent cells was due to
alterations in levels of 20S proteasomes, PA28 and 19S regula-Fig. 2. Analysis of the eﬀect of passage number on changes induced by
IFN-c. WI38 human embryonic ﬁbroblasts at increasing CPD were
incubated in the presence (n) or in the absence (h) of IFN-c. Cell
extracts prepared without added ATP were assayed for proteasome
CT-L activity in the presence of added ATP. These data cannot be
compared directly to those in Fig. 1 because total activity with suc-
Leu-Leu-Val-Tyr-AMC was assayed in these experiments rather than
proteasome-dependent activity. Gel ﬁltration analysis established that
10–30% of the total activity in early passage cells was accounted for by
other protease(s). Statistical analysis has shown that there is a
signiﬁcant increase in activity after treatment with IFN in early
passage cells (CPD23, CPD36, CPD39, P < 0.05) but there is no
signiﬁcant increase in activity after IFN treatment in late passage cells
(CPD 44, CPD 46).tory complexes, as well as those of the three IFN-c inducible
immunosubunits of the 20S proteasome, b1i, b2i, and b5i. As
shown in Fig. 3, IFN-c treatment induced an increase in the
protein expression levels of 20S proteasome inducible b-sub-
unit levels in early passage cells while there was no large
change in the levels of total 20S proteasome (a6 and a7) and
19S subunits (S4 and S5a). The induction of immunosubunit
expression levels was not observed in senescent cells. When
the expression levels of PA28 regulator were determined, in
contrast to the total loss of induction of immunosubunits fol-
lowing IFN-c treatment in senescent cells, a slight increase in
the level of PA28a was observed. These results were further
conﬁrmed by gel ﬁltration analysis (data not shown). In partic-
ular a striking exchange of the constitutive catalytic subunit b1
for b1i (LMP2) was observed after IFN-c treatment of early
passage cells and there was a marked increase in PA28-20S
proteasome and/or hybrid 19S-PA28 proteasome complexes.
Finally, these results were further veriﬁed when immunoﬂu-
orescence studies were performed (Fig. 4). These studies pro-
vide comparative data regarding the subcellular localization
of the immunoproteasome subunits in early and late passage
cells, demonstrating that regardless of the cellular state (prolif-
erating or senescent cells) the b1i, b2i and b5i subunits are local-
ized in both the nucleus and the cytoplasm. Moreover and in
agreement with the biochemical data, cell treatment with
IFN-c induced the immunoproteasome subunits in the early
passage cells but not in the senescent human diploid ﬁbro-
blasts. The accumulation of the immunoproteasome subunits
in IFN-c treated cells was not accompanied by an altered sub-
cellular distribution.
IFN-c treatment of young cells exhibited an enhanced
immunoﬂuorescence signal of all three immunosubunits. How-
ever, when senescent cells were treated with IFN-c, no change
in the immunoﬂuorescence signal was observed (Fig. 4b).
3.3. Induction of immunoproteasome subunits in conﬂuent
cultures
We examined whether the lack of response to IFN-c treat-
ment exhibited by senescent cells is a common feature ofEarly
S5a
2i
5i
1i
Rpt-2
Late
+IFN +IFN - -
Fig. 3. Immunoblot analysis of IFN-c induced changes in proteasome
complexes. WI38 lysates from early passage (25 CPD) and senescent
cells (44 CPD) that were incubated in the presence or absence of IFN-c
for 24 h, were separated by SDS–PAGE and immunoblotted with
antibodies speciﬁc for proteasome subunits: a7 and a6 for 20S
proteasomes, b1i, b2i, and b5i for immunoproteasomes, S4 and S5a
for 19S complexes/26S proteasomes and PA28a for the IFN-c
inducible 11S regulator. In senescent cells, levels of constitutive
proteasome beta catalytic subunits are substantially decreased [15].
Fig. 4. Eﬀects of IFN-c on cellular morphology and subcellular
distribution of proteasomes. Confocal microscopy immunolocalization
of b1i, b2i and b5i, proteasome catalytic subunits in control (no IFN)
and IFN-c treated (+IFN) early (a) and late passage (b) human
ﬁbroblasts. Antibodies used are indicated at the left of the micro-
graphs. All the immunoproteasome subunits assayed were immunolo-
calized in both the nucleus (n) and the cytoplasm (arrows). IFN-c
treatment induced higher levels of the immunoﬂuorescent signal only
in the early passage cells but does not alter the subcellular distribution
of the three immunoproteasome subunits. Bars: 10 lM.
β- actin
Exp. Confl.
PA28α
β5i
β2i
β1i
α6
Rpt6
Fig. 5. Proteasome subunit levels in extracts prepared from exponen-
tially growing and conﬂuent WI38 ﬁbroblasts. Immunoblot analysis of
proteasome subunits in cell extracts prepared from early passage cells
in exponential growth and under conﬂuent conditions using subunit
speciﬁc antibodies as indicated. Data are from a representative
experiment with subunit speciﬁc antibodies for total 20S proteasomes
(a6), 26S proteasomes (Rpt 6), immunoproteasomes (b1i, b2i, b5i), and
11S regulator (PA28a).
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proteasome activities between exponentially growing and
growth arrested cells without recording any major diﬀerences
(data not shown). In these cultures, we have also examined
by immunoblotting and gel ﬁltration analysis the protein
expression levels of constitutive and inducible proteasome sub-
units. This analysis revealed substantial changes in proteasome
complexes associated with growth arrest. There was only a
slight change in level of a6 20S proteasome subunit between ar-
rested and exponentially grown cells (Fig. 5). However, there
were striking increases in the expression levels of immunosu-
bunits (b1i, b2i and b5i) and PA28, and a substantial decrease
in Rpt6 and other subunits of the 19S complex (Fig. 5). The
results indicate a shift from 26S proteasomes to PA28 protea-
some complexes upon conﬂuence/quiescence and further con-
ﬁrm that the lack of IFN-c induced expression of
immunosubunits observed in irreversibly growth arrested cells
is a characteristic of senescence.4. Discussion
The results presented here demonstrate a striking diﬀerence
in the regulation of immunoproteasome levels in replicative
senescence compared to constitutive proteasomes. There is a
marked decrease in constitutive proteasome catalytic subunits
and in 19S regulatory complex subunits in senescent WI38
ﬁbroblasts that causes an accumulation of ubiquitinated and
oxidized proteins and decreased ability to survive oxidative
stress [15]. In contrast, there is no such decrease in immuno-
proteasome subunit levels, although the ability of IFN-c to in-
duce immunosubunits is lost in senescent cells.
The mechanisms of regulation of proteasome genes and the
expression of diﬀerent types of regulatory complexes are only
poorly understood. Recent studies have demonstrated re-
sponses to viral infection [6], glucocorticoid treatment [19],
overexpression of constitutive catalytic subunits [20], and
treatment with proteasome inhibitors [21]. The levels of consti-
tutive or immuno-20S proteasome complexes appears to be
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case of immunoproteasomes, the induction of all three immun-
osubunits by IFN-c is regulated by the same transcription fac-
tor, interferon response factor 1 (IRF1) [22–24]. On the other
hand, levels of expression of IFN-c inducible PA28 subunits
appear to be regulated separately [25], and governed at least
in part by NFjB. Our results with senescent cells also demon-
strate that changes in immunoproteasome levels are not always
mirrored by changes in inducible PA28.
Immunoproteasome levels are increased in conﬂuent hu-
man WI38 ﬁbroblast cultures during the reversible growth ar-
rest caused by contact inhibition (Fig. 5) as reported for
other primary cell lines [26]. In contrast, such an increase
in immunosubunit levels is not observed in the irreversible
growth arrest of senescent cells. The lack of increase in
immunosubunit levels and the inability of IFN-c to induce
them in senescent cells are not due to loss of cell viability
or capacity for protein synthesis in senescent cells, since
senescent cells are viable and capable of synthesizing proteins
[9]. It is well established that senescent ﬁbroblasts exhibit
alterations in the major signalling pathways and the pheno-
type of replicative senescence is accompanied with changes
in the expression levels of about 0.5% of human genes (re-
viewed in [27]). Moreover, the results presented are consistent
with results of other groups that show a lack of responsive-
ness of senescent cells as compared to young cells to a variety
of cytokines including tumour necrosis factor, interleukin-1,
ﬁbroblast growth factor, and epidermal growth factor [28–
30]. However, some proteins induced by IFN-c are known
to contribute to the senescent state [10–13], suggesting that
the response to IFN-c is not lost and the lack of induction
of immunosubunit levels does not result from a complete loss
of IFN signalling. Nevertheless, the lack of IFN-c induced in-
crease in immunoproteasome subunits appears to be a char-
acteristic of the irreversible growth arrest of senescent cells,
a ﬁnding that may suggest alterations in the transcriptional
activity of IRF-1.
The precise function of immunoproteasomes and the signif-
icance of their retention in senescent cells are not yet clear.
During viral infection constitutive proteasomes are largely re-
placed with immunoproteasomes [6], presumably to alter the
pool of available peptides for presentation on MHC class I
molecules. The observed enrichment of immunoproteasomes
at the ER [5] may reﬂect the site of assembly and enhanced rate
of synthesis of immunoproteasomes following treatment with
IFN-c [31], as well as their possible direct interaction with
the TAP transporter [32] for more eﬃcient antigen presenta-
tion. The retention of immunoproteasomes in senescent cells
while constitutive proteasomes are dramatically reduced [15]
points to major functional diﬀerences between the two cata-
lytic types of core 20S proteasomes. Understanding mecha-
nisms of senescence and the regulation of protein
degradation is important because cells bypass senescence in
cancer development [9], and proteasome inhibitors, that can
also induce a senescent phenotype [15], are proving to be
eﬀective treatment for certain types of cancers [33,34].
Furthermore, the regulation of immunoproteasomes during
senescence is an important issue since failure of the immune
system to function properly in older people [35] renders them
prone to diseases. Revealing the mechanisms of immunopro-
teasome regulation would highlight possible anti-ageing
strategies.Acknowledgements: This work was supported by a grant (PROTEO-
MAGE) from the European Commission. We thank Dr. R. Matsas
for the use of microscopy facilities.References
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